ESC: Novartis looks for the bright side in flopped Entresto heart failure study

Novartis has held high hopes for cardiovascular med Entresto as peak sales estimates reached $5 billion. Now, with a trial setback standing in its way, Novartis is looking at the bright side—Entresto may have flopped, but it was a “narrow miss.”